Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Last trade$1,405.65
Day change-$26.02 (-1.82%)
Day range$1,402.39 – $1,439.03
Volume1,542,033
Market cap$1.28T
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.28T
Price / earnings
46.24×
Price / book
31.67×
Price / sales
14.75×
EV / sales
15.27×
EV / EBITDA
28.39×
Profitability
Earnings per share
$30.96
Return on assets
18.63%
Return on equity
68.49%
Dividend yield
0.47%
Liquidity and leverage
Debt / equity
1.23×
Current ratio
1.39×
Quick ratio
1×
Cash ratio
0.1×
Cash flow
Price / cash flow
41.61×
Price / free cash flow
64.86×
Free cash flow
$19.66B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LLY, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$24.4B
$22.97B
$19.8B
$19.29B
$17.6B
$15.56B
$12.73B
$13.53B
Cost of revenue
$3.93B
$3.27B
$3.58B
$3.37B
$3.01B
$2.45B
$2.23B
$2.4B
Gross profit
$20.46B
$19.71B
$16.22B
$15.92B
$14.59B
$13.11B
$10.5B
$11.13B
Selling, general and administrative
$3.13B
$3.43B
$2.93B
$3.13B
$2.74B
$2.75B
$2.47B
$2.42B
Research and development
$4.25B
$3.82B
$3.51B
$3.8B
$3.47B
$3.34B
$2.73B
$3.02B
Total operating expenses
$11.86B
$10.73B
$7.31B
$7.55B
$7.23B
$6.24B
$6.81B
$5.98B
Operating income
$8.61B
$8.98B
$8.92B
$8.37B
$7.37B
$6.87B
$3.7B
$5.15B
Interest expense
$0
$345M
$0
$0
$0
$249M
$0
$0
Income before taxes
$8.41B
$9.25B
$8.85B
$8.27B
$7.23B
$6.78B
$3.46B
$5.04B
Income taxes
$1.96B
$2.15B
$1.45B
$1.63B
$1.65B
$1.12B
$697M
$628.5M
Net income
$6.45B
$7.1B
$7.4B
$6.64B
$5.58B
$5.66B
$2.76B
$4.41B
Net income attributable to common shareholders
$6.45B
$7.1B
$7.4B
$6.64B
$5.58B
$5.66B
$2.76B
$4.41B
EBITDA
$13.64B
$12.99B
$10.29B
$9.57B
$8.86B
$7.5B
$5.77B
$6.17B
Basic earnings per share
$7.23
$7.95
$8.27
$7.41
$6.22
$6.30
$3.07
$4.90
Diluted earnings per share
$7.22
$7.94
$8.26
$7.39
$6.21
$6.29
$3.06
$4.88
Recent news
Company coverage with links to the original publishers.
The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.
Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.
The Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed healthcare sector ETF with $4.08 billion in assets and a low 0.08% expense ratio. Year-to-date performance is up 21.32%, with top holdings including Eli Lilly, Johnson & Johnson, and Abbvie. The ETF carries a Zacks ETF Rank of 3 (Hold) and offers medium-risk diversified exposure to 348 healthcare companies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 13, 2026
$1.73
Dec 10, 2026
recurring
Aug 14, 2026
$1.73
Sep 10, 2026
recurring
May 15, 2026
$1.73
Jun 10, 2026
recurring
Feb 13, 2026
$1.73
Mar 10, 2026
recurring
Nov 14, 2025
$1.50
Dec 10, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.